Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients

2013; SAGE Publishing; Volume: 34; Issue: 5 Linguagem: Inglês

10.1007/s13277-013-0854-4

1423-0380

Marcelo Langer Wroclawski, Ary Serpa Neto, Fernando Luiz Affonso Fonseca, Oseas Castro-Neves-Neto, Alexandre Saad Feres Lima Pompeo, Marcos Tobías Machado, Antonio Carlos Lima Pompeo, Auro del Giglio,

Cancer Genomics and Diagnostics

The aim of this study was to evaluate the diagnostic and potential prognostic value of cell-free plasma DNA (CF-pDNA) in patients with suspected or histologically proven prostate cancer (PCa). We included 133 men with a diagnosis of PCa and 33 controls. PCa patients had blood samples prospectively drawn every 3 months for 2 years. CF-pDNA was measured by spectrophotometry. Considering a cut-off value of 140 ng/mL of CF-pDNA the area under the curve was of 0.824(0.757-0.879 with a sensitivity = 66.2 % and a specificity = 87.9 %) and the positive and negative likelihood ratio were of 5.46 and 0.39, respectively. CF-pDNA tends to decrease slightly and return to baseline values in about a week after biopsy. There was no statistical significant correlation between CF-pDNA levels at study entry with PSA, Gleason score, stage and biochemical recurrence free survival (BRFS). However, with a mean follow-up of 13.5 months, we could observe a significant shorter BRFS for patients with at least one value above 140 ng/mL of CF-pDNA during follow-up (p = 0.048). CF-pDNA is a potentially valuable biomarker for PCa diagnosis and a potential tool for the follow-up of patients with PCa.